The microbiome sequencing outsourcing services market is projected to grow from USD 2.00 billion in 2025 to USD 9.21 billion by 2035 because microbiome studies need specialized sequencing, quality systems, and bioinformatics that many drug developers and researchers prefer to buy from expert service providers. Microbiome therapeutics and clinical trials, larger research cohorts, shotgun and long-read sequencing, demand for GxP-compliant services, and new clients in food, agriculture, and consumer health support very strong growth, lifting the market to USD 4.29 billion by 2030 and sustaining a CAGR of 16.50% throughout the forecast timeframe.
Analyst View: We built the estimate from the number of microbiome samples sequenced by outsourced service providers by technology, application, laboratory type, end user and region, multiplied by average service prices per sample. Sample numbers reflect research and clinical activity and outsourcing rates, while prices reflect the shift to deeper shotgun and long-read sequencing and bioinformatics. The total was cross-checked against the microbiome service revenues of leading providers and against published estimates of outsourced microbiome sequencing, indicating a base-year market size slightly higher than prevailing industry estimates. The growth rate reflects strong demand from therapeutics and research, which we judge supports a slightly higher rate than comparable estimates, moderated by falling prices per sample.
The microbiome sequencing outsourcing services market is driven by increasing clinical trials for microbiome-based therapeutics and expanding research cohorts. Growing analytical complexity is encouraging outsourcing to specialized providers, while declining sequencing costs and adoption across food, agriculture, and pharmaceutical industries are broadening demand for outsourced services.
Market growth is constrained by declining prices per sample, inconsistent sequencing and analytical protocols, and concerns surrounding sensitive genomic data security. Lengthy clinical validation requirements and competition from laboratories investing in in-house sequencing infrastructure further challenge service providers' pricing power and customer acquisition.
Increasing demand for regulated clinical trial support and advanced long-read sequencing creates opportunities for specialized service providers. Expanding sequencing infrastructure across Asia Pacific, growing interest in strain-level analysis, integrated multi-omics service packages, and partnerships with consumer health companies offer additional avenues for market expansion.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Short-Read Sequencing: This segment accounted for 70.00% (USD 1.40 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 5.99 billion by 2035, expanding at a CAGR of 15.64% by 2035. Short-read sequencing, mainly sequencing by synthesis, leads because it delivers high accuracy at the lowest cost per sample and is the standard for 16S and shotgun microbiome studies.
Growth is supported by its ability to resolve full-length 16S genes, distinguish microbial strains, and characterize complete genomes, alongside expanding service offerings from sequencing providers.
Others include Sanger sequencing and emerging sequencing technologies.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Shotgun Metagenomics: This segment accounted for 44.00% (USD 0.88 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 3.84 billion by 2035, expanding at a CAGR of 15.87% from 2026 to 2035. Shotgun metagenomics is the largest application because it identifies bacteria, viruses and fungi at species and strain level and reveals functional genes, which drug developers and clinical researchers need.
Its adoption is supported by relatively low sequencing costs and suitability for large-scale microbiome studies, population screening, and routine microbial community profiling.
Increasing demand for insights into microbial gene expression and functional activity, rather than microbial presence alone, is driving its adoption in advanced research and therapeutic development.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Wet Lab: This segment accounted for 62.00% (USD 1.24 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 5.25 billion by 2035, expanding at a CAGR of 15.53% from 2026 to 2035. Wet laboratory services, including sample receipt, extraction, library preparation and sequencing, lead because they account for most of the cost of each project.
Dry Lab: Valued at USD 0.76 billion, equivalent to 38.00% of the market in 2025, dry laboratory services are forecast to reach USD 3.96 billion by 2035, registering a faster CAGR of 17.93%. Increasing complexity of microbiome datasets is driving demand for specialized bioinformatics, reference databases, statistical analysis, and data interpretation services.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Pharmaceutical & Biotechnology Companies: Leading the end-user category with a 54.00% share (USD 1.08 billion) in 2025, this segment is projected to reach USD 4.81 billion by 2035, registering a CAGR of 16.09%. Demand is driven by outsourcing requirements for microbiome therapeutics development, biomarker discovery, and clinical trials, particularly for specialized GxP-compliant sequencing services.
Academic and research institutes outsource sequencing to access capacity, expertise and lower costs for large studies.
Expanding microbiome applications across food processing, agriculture, animal health, and consumer wellness are driving demand for specialized outsourced sequencing and analytical services.
Analyst View: Segment values were allocated by matching outsourced sample volumes and prices to technologies, applications, laboratory types and end users, using provider portfolios and research and pipeline data. Short-read sequencing, shotgun metagenomics, wet lab services, and pharmaceutical clients lead. We expect long-read sequencing, metatranscriptomics, bioinformatics services and new industry clients to gain share.
| Region | 2025 Share | 2025 Value (USD Billion) | 2035 Value (USD Billion) | CAGR 2026-2035 |
| North America | 39.40% | 0.79 | 3.41 | 15.76% |
| Europe | 25.80% | 0.52 | 2.31 | 16.16% |
| Asia Pacific | 23.10% | 0.46 | 2.45 | 18.16% |
| Latin America | 6.40% | 0.13 | 0.57 | 16.16% |
| Middle East & Africa | 5.30% | 0.11 | 0.47 | 16.16% |
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
North America: This region accounted for 39.40% (USD 0.79 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 3.41 billion by 2035, expanding at a CAGR of 15.76% from 2026 to 2035. North America is the largest region because of its large microbiome therapeutics pipeline, pharmaceutical outsourcing and research funding, and many specialist providers.
Europe: The European market was valued at 25.80% (USD 0.52 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 2.31 billion by 2035, expanding at a CAGR of 16.16% during the forecast period. Europe has strong microbiome research and specialist CROs such as Cmbio in Denmark and Eurofins laboratories.
Asia Pacific: Asia Pacific captured a 23.10% (USD 0.46 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 2.45 billion by 2035, expanding at a CAGR of 18.16% by 2035. Asia Pacific is the fastest-growing region because of large low-cost sequencing capacity at providers such as Novogene and BGI in China, and growing research in Japan, South Korea, Australia and India.
Latin America: Latin America generated USD 13.14 million in revenue during 2025, equivalent to 4.50% of the global market and is projected to reach USD 0.57 billion by 2035, expanding at a CAGR of 16.16% from 2026 to 2035. Latin America is supported by academic and agricultural microbiome research in Brazil.
Middle East & Africa: This region accounted for 5.30% (USD 0.11 billion) of the microbiome sequencing outsourcing services market in 2025 and is projected to reach USD 0.47 billion by 2035, expanding at a CAGR of 16.16% by 2035. The Middle East and Africa are supported by genomics investment in Gulf countries.
Analyst View: Regional shares were built from outsourced microbiome sequencing in each region. North America leads because of its pharmaceutical and research demand. We assign Asia Pacific the highest growth premium because sequencing capacity is expanding fastest there.
| Rank | Company Name | Market-Specific Revenue (USD Billion) | 2025 Share | Key Products / Business | Headquarters |
| 1 | Novogene | 0.24 | 12.00% | Microbiome and metagenomic sequencing | China |
| 2 | BGI Genomics | 0.18 | 9.00% | Microbiome sequencing services | China |
| 3 | Azenta (GENEWIZ) | 0.10 | 5.00% | Amplicon and metagenomic sequencing | United States |
| 4 | Eurofins Genomics | 0.10 | 5.00% | Microbiome sequencing services | Luxembourg |
| 5 | Psomagen | 0.08 | 4.00% | Microbiome sequencing services | United States |
| 6 | Cmbio | 0.05 | 2.50% | Microbiome CRO and multi-omics services | Denmark |
| 7 | Zymo Research | 0.05 | 2.50% | ZymoBIOMICS sequencing services | United States |
| 8 | CD Genomics | 0.04 | 2.00% | Microbiome sequencing services | United States |
| 9 | Microbiome Insights | 0.02 | 1.00% | Microbial sequencing services | Canada |
| 10 | MR DNA | 0.02 | 1.00% | Microbiome sequencing services | United States |
Note: Company revenues and shares are 2025 estimates.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Novogene led the microbiome sequencing outsourcing services market with an estimated 12.00% (USD 0.24 billion) of 2025 revenue, followed by BGI Genomics at 9.00% (USD 0.18 billion) and Azenta (GENEWIZ) at 5.00% (USD 0.10 billion). Novogene leads with very large sequencing capacity and broad microbiome and metagenomic services for clients worldwide. BGI Genomics offers microbiome sequencing services at scale, and Azenta provides amplicon and metagenomic sequencing through GENEWIZ. Eurofins Genomics, Psomagen, Cmbio, Zymo Research, CD Genomics, Microbiome Insights and MR DNA compete through sequencing services, microbiome CRO and multi-omics expertise, integrated kits and services, and specialised microbial sequencing.
The top 10 companies accounted for an estimated 44.00% (USD 0.88 billion) of 2025 revenue, while the remaining 56.00% (USD 1.12 billion) was shared among many academic core facilities, regional laboratories and specialist microbiome CROs. The microbiome sequencing outsourcing services market is fragmented, and competition centres on data quality, turnaround time, bioinformatics depth, GxP and CLIA compliance, price per sample and scientific support. Specialist microbiome CROs are consolidating to offer end-to-end services for drug developers.
The microbiome sequencing outsourcing ecosystem links kit and sequencing platform suppliers with service providers, bioinformatics tools, clients and regulators.
| Ecosystem Stage | Role in the Market | Key Companies |
| Kits & Platforms | Supply reagents and sequencers | Illumina, Oxford Nanopore, PacBio, QIAGEN, Zymo |
| Service Providers | Sequence samples | Novogene, BGI, Azenta, Eurofins, Psomagen |
| Specialist CROs | Run regulated microbiome studies | Cmbio, Microbiome Insights, MR DNA |
| Bioinformatics | Analyse and interpret data | Databases and analysis platforms |
| Clients | Commission studies | Pharma, biotech, academia, food and agri firms |
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
The Towards Healthcare Companies Quadrant positions key participants in the microbiome sequencing outsourcing services market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity and partnerships. Positions reflect each company's estimated 2025 outsourced microbiome sequencing revenue and our assessment of its service depth, quality and innovation.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Leaders: Novogene, BGI Genomics, Azenta (GENEWIZ), Eurofins Genomics and Psomagen combine large microbiome sequencing revenue with broad services and capacity.
Innovators: Cmbio, Zymo Research, CD Genomics, Microbiome Insights and MR DNA bring specialised microbiome expertise and regulated services.
By Technology
By Application
By Laboratory Type
By End User
By Region
The microbiome sequencing outsourcing services market was defined as microbiome sequencing and bioinformatics services performed by contract research organisations, genomics service providers and specialist laboratories for clients, worldwide. The 2025 base year was built bottom-up from outsourced microbiome samples by technology, application, laboratory type, end user and region, and average service prices, and checked top-down against the microbiome service revenues of leading providers. Segment, regional and company values were allocated from technologies, applications, laboratory types, end users and regional activity. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.
Analyst View: The microbiome sequencing outsourcing services market is growing quickly as drug developers, researchers and new industries rely on specialist providers for microbiome sequencing and analysis. Our estimate links demand to outsourced sample volumes and prices, so the forecast follows research funding, therapeutics pipelines and outsourcing rates. The main upside comes from therapeutics trials and multi-omics, while the main risks are falling prices and lack of standardisation.
